<?xml version='1.0' encoding='utf-8'?>
<document id="30171694"><sentence text="CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib." /><sentence text="This study investigated the effect of itraconazole, a strong dual inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), on the single dose pharmacokinetics of leniolisib"><entity charOffset="38-50" id="DDI-PubMed.30171694.s2.e0" text="itraconazole" /></sentence><sentence text=" In order to differentiate the specific contribution of CYP3A from P-gp, the potential interaction with quinidine, a strong inhibitor of P-gp but not CYP3A, was studied as well"><entity charOffset="104-113" id="DDI-PubMed.30171694.s3.e0" text="quinidine" /></sentence><sentence text=" Using a fixed-sequence, 3-way crossover design, 20 healthy male subjects received single oral doses of 10 mg leniolisib during three phases separated by a washout: (1) leniolisib alone, (2) 200 mg itraconazole once daily for 9 days plus leniolisib on day 5, and (3) 300 mg quinidine administered 1 h before and 3 h after leniolisib"><entity charOffset="198-210" id="DDI-PubMed.30171694.s4.e0" text="itraconazole" /><entity charOffset="274-283" id="DDI-PubMed.30171694.s4.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.30171694.s4.e0" e2="DDI-PubMed.30171694.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30171694.s4.e0" e2="DDI-PubMed.30171694.s4.e1" /></sentence><sentence text=" Itraconazole increased the leniolisib oral drug exposure (AUCinf ) by on average 2"><entity charOffset="1-13" id="DDI-PubMed.30171694.s5.e0" text="Itraconazole" /><entity charOffset="28-38" id="DDI-PubMed.30171694.s5.e1" text="leniolisib" /><pair ddi="false" e1="DDI-PubMed.30171694.s5.e0" e2="DDI-PubMed.30171694.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30171694.s5.e0" e2="DDI-PubMed.30171694.s5.e1" /></sentence><sentence text="1-fold, whereas the peak drug concentration (Cmax ) was less impacted (1" /><sentence text="25-fold)" /><sentence text=" The terminal elimination half-life (T1/2 ) of leniolisib was also increased by ~2-fold"><entity charOffset="47-57" id="DDI-PubMed.30171694.s8.e0" text="leniolisib" /></sentence><sentence text=" Neither oral AUCinf nor Cmax or T1/2 was found to be altered by quinidine"><entity charOffset="65-74" id="DDI-PubMed.30171694.s9.e0" text="quinidine" /></sentence><sentence text=" These findings suggest that the interaction with itraconazole occurred mainly systemically through inhibition of CYP3A, and corroborate our in vitro findings that leniolisib is neither a sensitive CYP3A substrate nor a relevant in vivo substrate for intestinal or hepatic P-gp"><entity charOffset="50-62" id="DDI-PubMed.30171694.s10.e0" text="itraconazole" /></sentence><sentence text=" Assuming itraconazole levels achieved complete inhibition of CYP3A, the fractional contribution of CYP3A to the overall disposition of leniolisib is estimated to be about 50%"><entity charOffset="10-22" id="DDI-PubMed.30171694.s11.e0" text="itraconazole" /><entity charOffset="136-146" id="DDI-PubMed.30171694.s11.e1" text="leniolisib" /><pair ddi="false" e1="DDI-PubMed.30171694.s11.e0" e2="DDI-PubMed.30171694.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30171694.s11.e0" e2="DDI-PubMed.30171694.s11.e1" /></sentence><sentence text=" The concomitant use of leniolisib with strong inhibitors of CYP3A as well as strong and moderate inducers of CYP3A is best avoided"><entity charOffset="24-34" id="DDI-PubMed.30171694.s12.e0" text="leniolisib" /></sentence><sentence text="" /></document>